title: Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
abstract: This study was performed to investigate the features and outcome of patients with therapy-related chronic myeloid leukemia (TR-CML) who were treated with tyrosine kinase inhibitors (TKIs). The analysis included 308 patients with CML in the chronic phase who were extracted from the CML Cooperative Study Group database. Of these patients, 11 (3.6%) were identified as having TR-CML. No differences in age, sex, white blood cell count, hemoglobin level, platelet count, or European Treatment and Outcome Study risk were observed between patients with TR-CML vs. de novo CML. However, the responses of TR-CML patients to TKIs (6, 3, and 2 received imatinib, nilotinib, and dasatinib, respectively) were excellent; all achieved major or deep molecular response. Furthermore, the outcomes of TR-CML patients were relatively favorable; the 3-year event-free survival rates in the TR-CML and de novo CML patients were 100% and 94%, respectively; the difference was not statistically significant. In conclusion, our study showed that TR-CML patients could achieve a good clinical course with TKI therapy. Detailed investigations of TR-CML may provide new insights into CML biology.
authors.affiliation: Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. Electronic address: iriyama.noriyoshi@nihon-u.ac.jp.
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Iriyama
authors.affiliation: Departments of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
authors.forename: Michihide
authors.initials: M
authors.lastname: Tokuhira
authors.affiliation: Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Tomoiku
authors.initials: T
authors.lastname: Takaku
authors.affiliation: Division of Hematology, Department of Medicine, Juntendo University Nerima Hospital, Tokyo, Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Sato
authors.affiliation: Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Maho
authors.initials: M
authors.lastname: Ishikawa
authors.affiliation: Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Nakazato
authors.affiliation: Department of Hematology, Juntendo University Urayasu Hospital, Urayasu, Japan.
authors.forename: Kei-Ji
authors.initials: KJ
authors.lastname: Sugimoto
authors.affiliation: Department of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.affiliation: Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Fujioka
authors.affiliation: Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.affiliation: Departments of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kizaki
authors.affiliation: Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Norio
authors.initials: N
authors.lastname: Komatsu
authors.affiliation: Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
authors.forename: Norio
authors.initials: N
authors.lastname: Asou
authors.affiliation: Department of Hematology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kawaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000069439:Dasatinib / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib
keywords: Prognosis; Therapy-related chronic myeloid leukemia; Tyrosine kinase inhibitor